嵌合抗原受体T细胞治疗后低丙种球蛋白血症的研究进展  

Progress of hypogammaglobulinemia after chimeric antigen receptor T-cell therapy

作　　者：张琪 肖毅[1] Zhang Qi;Xiao Yi(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,武汉430030

出　　处：《白血病．淋巴瘤》2024年第6期381-384,共4页Journal of Leukemia & Lymphoma

摘　　要：嵌合抗原受体T细胞(CAR-T)治疗是血液肿瘤治疗领域的重大突破, 但CAR-T疗法在发挥强大疗效的同时伴随着一系列不良反应, 其中低丙种球蛋白血症较常见, 易增加患者感染风险, 探讨这一不良反应的发生机制及干预策略对于患者的预后有着重要意义。文章就CAR-T治疗后发生低丙种球蛋白血症的机制、影响因素、预防和管理策略的研究进展进行综述。Chimeric antigen receptor T-cell(CAR-T)therapy is a major breakthrough in the treatment of hematologic tumors,but its powerful efficacy is accompanied with a series of side effects,including hypogammaglobulinemia which is more common and is easy to increase the risk of infection in patients,and thus it is critical to investigate the mechanism of the side effects and to work out intervention strategies for the prognosis of patients.The paper reviews the research progress of the mechanisms,influencing factors,prevention and management strategies for hypogammaglobulinemia after CAR-T therapy.

关 键 词：低丙种球蛋白血症 嵌合抗原受体T细胞 静脉注射用免疫球蛋白 免疫球蛋白G 

分 类 号：R733[医药卫生—肿瘤]